
Unvarnished takes on Big Pharma strategy, M&A patterns, and competitive positioning. What CEOs are actually signaling—before Wall Street sees it
| Platform | Pricing | Freemium | Publishes | Weekly | |
|---|---|---|---|---|---|
| Issues | 117 | Founded | 3 years ago | Last Issue | 9 days ago |
| Active | |||||

New color scheme for the LWTB image. What do you think?
Welcome back to Last Week Tonight in BioPharma (LWTB). What a week!
Abbvie looks to buy Apogee. Neumora watched navacaprant flame out in both KOASTAL-2 and KOASTAL-3, sending the sto...
Three under-the-radar cell therapy readouts from ASCO 2026 and where the near-term commercial future for this class may lie
Traditional autologous ex vivo cell therapy has largely fallen out of favor. Attention (and dollars) are far more f...
Welcome back to Last Week Tonight in BioPharma (LWTB). What a week!
GSK dropped its biggest deal ever, paying $10.6 billion for Nuvalent. Tango therapeutics wows with new PDAC combo data. Lots of GLP-1 data presented at the ADA 2026 confer...
Sac-TMT may be unlike other TROP2 ADCs and poses a real threat to the PD-1xVEGF class in 1L NSCLC
Frontline (1L) lung cancer always gets a ton of attention. It is arguably the single most important indication set in all of the KEYTRUDA (pe...
Welcome back to Last Week Tonight in BioPharma (LWTB). What a week!
Daraxonrasib steals the show at ASCO, Otsuka leaves room for competitors in IgAN, a potential new market opportunity for CAR-T, another big longevity company raise, and mu...
Subscribers, engagement, traffic and sponsorship for Big Pharma Sharma.
| Subscribers | Engagement | 72 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
How this newsletter ranks in the official Substack charts.
| #177 |
The writers behind this newsletter.
Drug Strategist. Delivering insider analyses and insights on all things BioPharma.
You can find recent issues that have been published by Big Pharma Sharma on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
To see how many people subscribe to Big Pharma Sharma, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
Newsletter advertising can be extremely effective when it's done right. Before you pitch Big Pharma Sharma as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Big Pharma Sharma using the contact information provided and ask for a copy of their media kit.
Scroll up to where it says Related Newsletters to see other publications like Big Pharma Sharma. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.